Covidien plc 4

4 · Covidien plc · Filed Dec 5, 2013

Form 4

Period: 2013-12-05

Senior Vice President

Transactions

Exercise/Conversion
Stock Option (Right to Buy)
2013-12-05−5,182→ 15,548 total
Exercise: $52.53Exp: 2022-12-02→ Ordinary Shares (5,182 underlying)
Exercise/Conversion
Ordinary Shares
2013-12-05$42.39/sh+6,440$272,992→ 34,725 total
Exercise/Conversion
Ordinary Shares
2013-12-05$52.53/sh+5,182$272,210→ 50,884 total
Exercise/Conversion
Ordinary Shares
2013-12-05$49.48/sh+678$33,547→ 51,562 total
Exercise/Conversion
Stock Option (Right to Buy)
2013-12-05−678→ 1,357 total
Exercise: $49.48Exp: 2021-06-30→ Ordinary Shares (678 underlying)
Exercise/Conversion
Stock Option (Right to Buy)
2013-12-05−5,712→ 5,713 total
Exercise: $39.18Exp: 2020-11-30→ Ordinary Shares (5,712 underlying)
Exercise/Conversion
Ordinary Shares
2013-12-05$39.18/sh+5,712$223,796→ 40,437 total
Exercise/Conversion
Ordinary Shares
2013-12-05$43.44/sh+5,265$228,712→ 45,702 total
Sale
Ordinary Shares
2013-12-05$67.33/sh−23,277$1,567,199→ 28,285 total
Exercise/Conversion
Stock Option (Right to Buy)
2013-12-05−5,265→ 0 total
Exercise: $43.44Exp: 2019-11-30→ Ordinary Shares (5,265 underlying)
Exercise/Conversion
Stock Option (Right to Buy)
2013-12-05−6,440→ 12,881 total
Exercise: $42.39Exp: 2021-11-30→ Ordinary Shares (6,440 underlying)

Footnotes (3)

[F1]The price reported is the weighted average price. Shares were sold in multiple transactions at prices ranging from $67.32 to $67.37. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a securityholder of the Issuer, full information regarding the number of shares sold at each price.
[F2]Adjusted in connection with the spin-off of Covidien's pharmaceuticals business.
[F3]Options become exercisable in equal installments on each of the first, second, third and fourth anniversary of the grant date.

Documents

1 file